Tectonic Therapeutic (TECX) Company Overview

Profile

Full Name:

Tectonic Therapeutic, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Indexes:

Not included

Description:

Tectonic Therapeutics (TECX) is a biotechnology company focused on developing innovative treatments for serious diseases. They use advanced technology to create new medicines that target specific health issues, aiming to improve patient outcomes and enhance the quality of life for those affected by various conditions.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jun 21, 2024

Analyst ratings

Recent major analysts updates

Jan 31, 25 Wells Fargo
Overweight
Nov 20, 24 Raymond James
Outperform
Nov 12, 24 Wells Fargo
Overweight
Nov 11, 24 Leerink Partners
Outperform
Aug 22, 24 Wells Fargo
Overweight
Jul 24, 24 Leerink Partners
Outperform
Jun 26, 24 Piper Sandler
Overweight
Jun 24, 24 TD Cowen
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Tectonic Announces $185 Million Private Placement
Tectonic Announces $185 Million Private Placement
Tectonic Announces $185 Million Private Placement
TECX
globenewswire.comFebruary 3, 2025

WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc.  (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $185.0 million.

Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
TECX
globenewswire.comJanuary 30, 2025

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein. The interim data showed that a single intravenous dose of TX45 resulted in meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). In the trial, TX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events.

Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
TECX
seekingalpha.comJanuary 5, 2025

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension, showing promise in early clinical trials. TX45's extended half-life and monthly dosing address limitations of native relaxin, positioning it as a potential best-in-class therapeutic. With favorable phase 1a data and ongoing phase 1b and 2 trials, Tectonic's TX45 could become a market leader, potentially attracting interest from potential biopharma acquirers.

Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
TECX
globenewswire.comNovember 11, 2024

WATERTOWN, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced detailed results from the Phase 1a clinical trial of its lead asset, TX45, a long-acting, Fc-relaxin fusion protein. The poster will be presented at the American Heart Association (AHA) Scientific Sessions on November 16, 2024 from 3-4pm EST in Chicago, Illinois. Favorable topline results from the TX45 Phase 1a clinical trial were announced on September 19, 2024, along with the dose selection for the TX45 APEX Phase 2 trial that is currently underway in patients with PH-HFpEF.

Tectonic Therapeutic: Interesting CV Disease Drug Developer
Tectonic Therapeutic: Interesting CV Disease Drug Developer
Tectonic Therapeutic: Interesting CV Disease Drug Developer
TECX
seekingalpha.comOctober 20, 2024

Tectonic Therapeutic's lead candidate TX45 showed positive phase 1 results for Group 2 Pulmonary Hypertension, driving the stock up over 100% in September. TX45 is an Fc-relaxin fusion molecule targeting the RXFP1 receptor, offering potential therapeutic benefits for hypertension and heart failure with preserved ejection fraction (HFpEF). Tectonic has a solid financial position with a market cap of $551mn, $185mn in cash reserves, and a cash runway extending into 2027.

Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
TECX
globenewswire.comSeptember 19, 2024

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the Phase 2 clinical trial

TECX Stock Earnings: Tectonic Therapeutic Misses EPS for Q2 2024
TECX Stock Earnings: Tectonic Therapeutic Misses EPS for Q2 2024
TECX Stock Earnings: Tectonic Therapeutic Misses EPS for Q2 2024
TECX
investorplace.comAugust 24, 2024

Tectonic Therapeutic (NASDAQ: TECX ) just reported results for the second quarter of 2024. Tectonic Therapeutic reported earnings per share of -$4.34.

Tectonic Therapeutic to Participate in September Investor Conferences
Tectonic Therapeutic to Participate in September Investor Conferences
Tectonic Therapeutic to Participate in September Investor Conferences
TECX
globenewswire.comAugust 20, 2024

WATERTOWN, Mass., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will present at the 2024 Wells Fargo Healthcare Conference being held in Boston on September 4-6, 2024 and participate in the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on September 4-6, 2024.

FAQ

  • What is the ticker symbol for Tectonic Therapeutic?
  • Does Tectonic Therapeutic pay dividends?
  • What sector is Tectonic Therapeutic in?
  • What industry is Tectonic Therapeutic in?
  • What country is Tectonic Therapeutic based in?
  • Is Tectonic Therapeutic in the S&P 500?
  • Is Tectonic Therapeutic in the NASDAQ 100?
  • Is Tectonic Therapeutic in the Dow Jones?
  • When was Tectonic Therapeutic's last earnings report?
  • When does Tectonic Therapeutic report earnings?
  • Should I buy Tectonic Therapeutic stock now?

What is the ticker symbol for Tectonic Therapeutic?

The ticker symbol for Tectonic Therapeutic is NASDAQ:TECX

Does Tectonic Therapeutic pay dividends?

No, Tectonic Therapeutic does not pay dividends

What sector is Tectonic Therapeutic in?

Tectonic Therapeutic is in the Healthcare sector

What industry is Tectonic Therapeutic in?

Tectonic Therapeutic is in the Biotechnology industry

What country is Tectonic Therapeutic based in?

Tectonic Therapeutic is headquartered in United States

Is Tectonic Therapeutic in the S&P 500?

No, Tectonic Therapeutic is not included in the S&P 500 index

Is Tectonic Therapeutic in the NASDAQ 100?

No, Tectonic Therapeutic is not included in the NASDAQ 100 index

Is Tectonic Therapeutic in the Dow Jones?

No, Tectonic Therapeutic is not included in the Dow Jones index

When was Tectonic Therapeutic's last earnings report?

Tectonic Therapeutic's most recent earnings report was on Nov 12, 2024

When does Tectonic Therapeutic report earnings?

The next expected earnings date for Tectonic Therapeutic is Feb 28, 2025

Should I buy Tectonic Therapeutic stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions